Juva Life Launches First In-House Branded Product: ‘Secret Sauce’ Concentrate – in Response to Market Segment Growth
Juva Life Launches First In-House Branded Product: ‘Secret Sauce’ Concentrate – in Response to Market Segment Growth
Vertically Integrated California Cultivator and Life Science Research Company Expands Strategically Into New Category
VANCOUVER, British Columbia, March 30, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today the launch of the Company’s first in-house branded product, a concentrate line called “Secret Sauce,” as part of a strategic effort to diversify wholesale lines into branded products.
“Expanding upon our successful five-star delivery service and flower products, Juva’s first in-house branded product represents a strategic decision to expand into high-growth product categories like concentrates,” said Doug Chloupek, CEO and Founder of Juva. “Our customers trust the quality, safety and transparency of our products. The Secret Sauce concentrate line is what our customers are asking for, and we look forward to expanding the Juva product offerings across more regions in California through both Juva Delivery and our strong retail partnerships.”
The concentrate brand launches at an ideal time in the market, with concentrates representing the fastest-growing category for cannabis products, accounting for 26.6% of market share, according to a recent report by ArcView, in partnership with BDS Analytics. Secret Sauce will be available through distributors and through Juva Delivery, a division of vertically integrated Juva Life, Inc., which also offers contactless pre-payment options through Paytender, a secure, fee-free online payment service.
Each product begins with meticulously selected cultivars grown at the Company’s 30,000-square-foot Stockton, California, cannabis cultivation facility. Once harvested and cured, the material is then moved to a manufacturing partner for final processing and statewide distribution. Currently available at select cannabis retail outlets in the California region, Secret Sauce will launch at additional storefronts in the coming weeks. To find available products locally in the Stockton Area, visit here. To find available products locally in the San Francisco Peninsula area, visit here.
Juva Life’s pharmaceutical research and life sciences division is working to identify the method of action behind cannabis’ anecdotal ability to control pain and inflammation. The Company recently identified non-cannabinoid compounds JUVA-019 and JUVA-041, on which the Company has filed patent applications and has conducted preclinical research showing that the compounds are effective as stand-alone compounds in inhibiting inflammation by modulating certain biomarkers in the body. JUVA-019 and JUVA-041, which the Company has nominated as drug candidates for further preclinical investigation, are currently advancing through phenotypic models of chronic diseases of aging.
The Company would also like to announce that on January 6, 2022, 3,175,000 stock options and 10,000,000 compensation warrants were canceled. On March 25, 2022, the Company granted 17,220,000 stock options exercisable at $0.32 per stock option for a period of 10 years to consultants, employees, and directors of the Company. The stock options have varying vesting terms.
ON BEHALF OF THE BOARD,
-Doug Chloupek-
Doug Chloupek, CEO and Founder
Juva Life Inc.
About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.
For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com
Forward Looking Statement
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Juva Life Announces Webinar Takeaways, Showcasing Increased Production Output, Operational Milestones and Pharmaceutical Advancements
Juva Life Announces Webinar Takeaways, Showcasing Increased Production Output, Operational Milestones and Pharmaceutical Advancements
Cannabis and Life Sciences Company Webinar Highlights Milestones, Growth and Future Plans
VANCOUVER, British Columbia, March 24, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today the successful completion of the Company’s corporate update webinar, which shared takeaways and pharmaceutical development updates from its research division.
“We are continuously refining our processes to make Juva the most profitable, efficient business in the cannabis and pharmaceutical industries,” said Doug Chloupek, CEO and Founder of Juva. “One of our major updates you’ll see in this webinar is the completion of our Stockton cultivation facility construction, which increased our output three-fold, without increasing base production costs. We are also pleased to share major advancements with our two proprietary compounds, JUVA-019 and JUVA-041.”
The Company’s webinar originally aired live on Zoom on March 23, 2022, and showcased the Company’s construction updates and advancements. The webinar also provided an update on its cannabis and pharmaceutical operations. Webinar viewers got to see updates on:
- Juva’s newly completed Stockton cultivation facility, which was previously under construction for 3.5 years
- Operational milestones such as Stockton Delivery, which is now fully online and operational
- Completion of the final phase of licensing for a downtown Redwood City retail store
- Ramped up R&D on Juva’s pharmaceutical side, completed for a fraction of the cost of traditional pharmaceutical research
- The newly revised JuLi Research Registry, which just received WIRB approval
Those interested in viewing the webinar recording can do so here: https://juvalife.com/investors/
ON BEHALF OF THE BOARD,
-Doug Chloupek-
Doug Chloupek, CEO and Founder
Juva Life Inc.
About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.
For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com
Forward Looking Statement
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Juva Life Announces Completion of Stockton, California, Cannabis Cultivation Facility, Doubling Harvest Capacity
Juva Life Announces Completion of Stockton, California, Cannabis Cultivation Facility, Doubling Harvest Capacity
Cannabis and Life Sciences Company Doubles Capacity of Stockton Cultivation Facility With Completed Construction
VANCOUVER, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today the completion of the final phase of construction at its 30,000-square-foot cannabis cultivation facility in Stockton, California.
“The successful completion of this expansion will effectively double the capacity of our Stockton cultivation facility,” said Doug Chloupek, CEO and Founder of Juva. “We are grateful for our hard-working teams that helped us successfully complete the expansion of this facility and we are excited to see the increase in revenue it will produce. Our focus as a company remains on the promising research on our two proprietary molecular compounds, JUVA-019 and JUVA-041, as we continue down our path to identify pharmacological compounds with potential to treat health effects such as inflammation in the human body.”
The completion of all construction doubles the number of cannabis flower cultivation rooms from three to six rooms, without increasing costs, and also maximizes the facility’s current systems. The final phase of construction cost about $2.6 million, whereas the total cost of construction for the facility was just about $12.5 million.
Juva had nine successful harvests in 2021 and the team is on schedule to have 33 planned harvests in 2022 with an average yield of 1.5 pounds per light, with a target of 2-2.5 pounds per light. There are currently 588 lights in the flower rooms and 196 in the vegetative room.
Additionally, the Company will be hosting a live Zoom webinar on March 23rd at 4pmET, which will showcase the construction updates and advancements of Juva, and provide an update on its cannabis and pharmaceutical operations. Those interested in viewing the webinar can join live, or watch the recording on the Juva website shortly after it airs.
To register to attend the webinar, please visit: https://us02web.zoom.us/webinar/register/WN_rDchFYF1QI6FovTi4uwOdw
ON BEHALF OF THE BOARD,
-Doug Chloupek-
Doug Chloupek, CEO and Founder
Juva Life Inc.
About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.
For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com
Forward Looking Statement
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Juva Life Launches Journal App, Offering Personal Health and Wellness Tracking for Cannabis Patients
Juva Life Launches Journal App, Offering Personal Health and Wellness Tracking for Cannabis Patients
Life Science Research & Vertically Integrated California Cultivator Offers App to Help Consumers Track Cannabis Effects on Their Health and Wellness
VANCOUVER, British Columbia, March 2, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today the launch of the Company’s Journal App, designed to help cannabis users and patients track their consumption, and gain insight into how cannabis products affect their health and wellness.
“We’re proud to be one of the first and only companies to offer consumers a daily tracking solution that provides them a closer look at how their cannabis use affects their personal health and wellness,” said Doug Chloupek, CEO and Founder of Juva. “One of Juva’s primary goals is to expand our industry’s knowledge of the medicinal effects of cannabis from a scientific perspective. The Journal App provides a personal tracking solution for our customers and it gives Juva information that compliments the data we collect via our research registry.”
Through the Journal App, cannabis consumers and anyone who uses hemp-based cannabidiol (CBD) products can track their symptoms, medication use and results. Consumers can track a variety of health ailments, while documenting the products they consumed, the effect they had on their specific symptoms and any side effects that may occur.
“In all industries, data is king. Through both the Journal App and our WIRB-approved registry, we are curating one of the largest repositories of real-world data on the medical effects of cannabis use, including consumption behavior and perceived effectiveness. While we remain committed to the privacy of our users, the data we are collecting will be beneficial from a regulatory and scientific standpoint and adds significant value to Juva’s intellectual property portfolio,” added Chloupek. “All user info associated with the Journal App and the WIRB-approved registry is protected by the strictest patient privacy laws in the world, so participants can rest assured their entries are 100% confidential; any data imputed is anonymized for patient privacy.”
Those interested in downloading the Journal App can do so here: https://shopjuva.com/journalapp/
The Company is also running a WIRB-approved multi-year study through its cannabis research registry. Once completed Juva will have one of the largest data sets of its kind and be able to leverage the data in both its nutraceutical wellness, drug development and clinical programs. This real-world observational data, overseen by physicians and clinicians, will be presented to various regulatory bodies to show the potential therapeutic benefits of cannabis and hemp-derived compounds.
Juva Life also has a pharmaceutical research and life sciences division, with a goal of identifying the mode of action behind cannabis’ anecdotal ability to regulate inflammation. The Company recently identified non-cannabinoid compounds JUVA-019 and JUVA-041, on which the Company has filed patent applications and has conducted preclinical research showing the compound is effective as a stand-alone compound in inhibiting inflammation by modulating certain biomarkers in the body. JUVA-019 and JUVA-041, which the Company has nominated as drug candidates for further preclinical investigation, are currently advancing through phenotypic models of chronic diseases of aging.
ON BEHALF OF THE BOARD,
-Doug Chloupek-
Doug Chloupek, CEO and Founder
Juva Life Inc.
About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.
For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com
Forward Looking Statement
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
